The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of triplet therapy with hypomethylating agent, venetoclax, and FLT3 inhibitor versus doublet therapy in FLT3-mutated acute myeloid leukemia.
 
Layal Sharrouf
No Relationships to Disclose
 
Amir Fathi
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Autolus; BMS; Daiichi Sankyo; Genentech; Genmab; Gilead Sciences; Immunocore (I); Kura Oncology; Pfizer; Prelude Therapeutics; Remix; Rigel; Schrodinger; SERVIER; Syndax; Takeda; Thermo Fisher Scientific
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Kura Oncology (Inst); SERVIER (Inst)
 
Noura Abbas
No Relationships to Disclose
 
Maher Abdul-Hay
Consulting or Advisory Role - Abbvie; Amgen; Autolus; Daiichi Sankyo; Incyte; Novartis; PureTech; SERVIER